Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

SION

Sionna Therapeutics Inc

Feb 06 • 04:00PM ET

36.11

+0.86 2.44 %

Healthcare • Biotechnology • USA • NASD

Feb 05, 3:01 PMInsider selling by director and major shareholder sparked significant intraday sell-off.

Held by: VTI XBI IWM VXF IBB IWO VTWO SCHA IWC DWAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.60	Insider Own	44.03%	Shs Outstand	44.46M	Perf Week	-14.55%
Market Cap	1.61B	Forward P/E	-	EPS next Y	-2.26	Insider Trans	-9.83%	Shs Float	24.98M	Perf Month	-16.43%
Enterprise Value	1.37B	PEG	-	EPS next Q	-0.54	Inst Own	55.53%	Short Float	12.22%	Perf Quarter	2.94%
Income	-70.68M	P/S	-	EPS this Y	87.52%	Inst Trans	-1.34%	Short Ratio	10.00	Perf Half Y	108.97%
Sales	0.00M	P/B	4.99	EPS next Y	-13.08%	ROA	-26.35%	Short Interest	3.05M	Perf YTD	-12.23%
Book/sh	7.23	P/C	6.49	EPS next 5Y	45.26%	ROE	-28.07%	52W High	45.00 -19.76%	Perf Year	-
Cash/sh	5.56	P/FCF	-	EPS past 3/5Y	-23.81% -	ROIC	-21.45%	52W Low	7.26 397.73%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	12.25% 9.10%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-22.20%	Oper. Margin	-	ATR (14)	3.36	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	25.61	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	39.60	Recom	1.44
Dividend Gr. 3/5Y	- -	Current Ratio	25.61	EPS Q/Q	20.90%	SMA20	-10.85%	Beta	4.15	Target Price	46.75
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	-12.41%	Rel Volume	1.44	Prev Close	35.25
Employees	41	LT Debt/Eq	0.02	Earnings	Nov 05 BMO	SMA200	31.56%	Avg Volume	305.40K	Price	36.11
IPO	Feb 07, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	5.02% -	Trades		Volume	440,028	Change	2.44%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-01-25	Downgrade	RBC Capital Mkts	Sector Perform → Underperform	$24
Nov-19-25	Initiated	BTIG Research	Buy	$50
Sep-03-25	Initiated	RBC Capital Mkts	Sector Perform	$22
Sep-03-25	Initiated	Raymond James	Strong Buy	$45
Mar-04-25	Initiated	TD Cowen	Buy
Mar-04-25	Initiated	Stifel	Buy	$32
Mar-04-25	Initiated	Guggenheim	Buy	$45

Feb-04-26 07:00AM	Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 (GlobeNewswire) -7.12%
Jan-05-26 07:00AM	Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-23-25 09:33AM	Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls (The Fly)
Nov-24-25 07:00AM	Sionna Therapeutics to Participate in Upcoming December Investor Conferences (GlobeNewswire)
Nov-14-25 06:00PM	Bitdeer, Pacira BioSciences, Garrett Motion, and More Stocks See Action From Activist Investors (Barrons.com) +7.92%
07:00AM	Loading…
Nov-05-25 07:00AM	Sionna Therapeutics Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-04-25 08:00AM	Sionna Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-31-25 05:42PM	Astria, Viridian Therapeutics, and More Stocks See Action From Activist Investors (Barrons.com) -5.63%
Oct-24-25 01:15PM	Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference (GlobeNewswire)
Oct-21-25 07:00AM	Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis (GlobeNewswire) +31.99%
Oct-01-25 04:05PM	Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference (GlobeNewswire)
Sep-15-25 12:00PM	All You Need to Know About Sionna Therapeutics, Inc. (SION) Rating Upgrade to Buy (Zacks)
Sep-09-25 09:55AM	Wall Street Analysts See a 66.51% Upside in Sionna Therapeutics, Inc. (SION): Can the Stock Really Move This High? (Zacks) +13.32%
Sep-08-25 08:00AM	Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer (GlobeNewswire) -9.92%
Aug-27-25 07:00AM	Sionna Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
07:00AM	Loading…
Aug-25-25 07:00AM	Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis (GlobeNewswire)
Aug-11-25 07:00AM	Sionna Therapeutics Reports Second Quarter 2025 Financial Results (GlobeNewswire) +13.36%
Jun-06-25 11:00AM	Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model (GlobeNewswire) +7.42%
Jun-04-25 01:54PM	Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial (Benzinga) +9.12%
07:00AM	Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis (GlobeNewswire)
Jun-03-25 07:00AM	Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-22-25 07:00AM	Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference (GlobeNewswire)
May-12-25 07:00AM	Sionna Therapeutics Reports First Quarter 2025 Financial Results (GlobeNewswire)
Apr-30-25 07:00AM	Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025 (GlobeNewswire)
Mar-20-25 07:00AM	Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-15-25 04:43PM	Sionna Therapeutics, Inc. (SION): Among Top Insider Purchases Last Month (Insider Monkey)
Mar-06-25 10:25AM	Is Sionna Therapeutics, Inc. (SION) Among Stocks With At Least $20 Million In Insider Spending Recently? (Insider Monkey) -5.04%
Mar-03-25 12:57PM	Sionna Therapeutics, Inc. (SION): Among Stocks With At Least $10 Million In Insider Spending Recently (Insider Monkey)
Feb-25-25 05:56AM	Sionna Therapeutics IPO: A strategic shift in the cystic fibrosis market (Pharmaceutical Technology) -13.37%
Feb-24-25 08:00AM	Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference (GlobeNewswire)
04:43PM	Loading…
Feb-17-25 04:43PM	Is Sionna Therapeutics (SION) Among Stocks Insiders Are Buying This Year? (Insider Monkey)
Feb-10-25 04:03PM	Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -11.04% -8.23%
Feb-06-25 07:51PM	Sionna Therapeutics Prices Upsized Initial Public Offering (GlobeNewswire)
03:13PM	Vertex challenger Sionna prices $191M IPO (BioPharma Dive)

Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in researching, developing and commercializing novel medicines for cystic fibrosis. It is focused on advancing a robust pipeline of small molecules and complementary CFTR modulators designed to deliver transformative clinical outcomes and improve the quality of life for individuals living with cystic fibrosis. The company was founded by Greg Hurlbut and Mark Munson in August 2019 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Thompson Peter A.	Director	Feb 03 '26	Sale	44.58	29,063	1,295,629	3,530,702	Feb 04 07:43 PM
Thompson Peter A.	Director	Feb 02 '26	Sale	44.57	1,890	84,237	3,559,765	Feb 04 07:43 PM
ORBIMED ADVISORS LLC	Director	Feb 03 '26	Sale	44.58	29,063	1,295,629	3,530,702	Feb 04 07:39 PM
ORBIMED ADVISORS LLC	Director	Feb 02 '26	Sale	44.57	1,890	84,237	3,559,765	Feb 04 07:39 PM
TPG GP A, LLC	10% Owner	Jan 22 '26	Sale	40.00	250,000	10,000,000	6,494,962	Jan 26 05:24 PM
Rise Fund Sling, L.P.	Stockholder	Jan 22 '26	Proposed Sale	41.77	195,667	8,173,011		Jan 22 08:47 PM
Rise Fund Sling II, L.P.	Stockholder	Jan 22 '26	Proposed Sale	41.77	54,333	2,269,489		Jan 22 08:47 PM
ORBIMED ADVISORS LLC	Director	Dec 24 '25	Sale	44.55	33,356	1,486,010	3,561,655	Dec 29 08:44 PM
Thompson Peter A.	Director	Dec 24 '25	Sale	44.55	33,356	1,486,010	3,561,655	Dec 29 08:42 PM
ORBIMED ADVISORS LLC	Director	Dec 17 '25	Sale	44.50	900	40,050	3,595,986	Dec 19 07:29 PM
ORBIMED ADVISORS LLC	Director	Dec 19 '25	Sale	44.49	875	38,929	3,595,011	Dec 19 07:29 PM
ORBIMED ADVISORS LLC	Director	Dec 18 '25	Sale	44.49	100	4,449	3,595,886	Dec 19 07:29 PM
Thompson Peter A.	Director	Dec 17 '25	Sale	44.50	900	40,050	3,595,986	Dec 19 07:24 PM
Thompson Peter A.	Director	Dec 19 '25	Sale	44.49	875	38,929	3,595,011	Dec 19 07:24 PM
Thompson Peter A.	Director	Dec 18 '25	Sale	44.49	100	4,449	3,595,886	Dec 19 07:24 PM
Fitzpatrick Jennifer	Chief Legal Officer	Dec 05 '25	Option Exercise	6.11	10,250	62,628	10,250	Dec 09 04:57 PM
Fitzpatrick Jennifer	Chief Legal Officer	Dec 05 '25	Sale	40.52	10,250	415,330	0	Dec 09 04:57 PM
JENNIFER R FITZPATRICK	Officer	Dec 05 '25	Proposed Sale	40.88	10,250	419,020		Dec 05 04:27 PM
ORBIMED ADVISORS LLC	Director	Nov 24 '25	Sale	44.54	94,583	4,212,727	3,610,376	Nov 26 06:45 PM
ORBIMED ADVISORS LLC	Director	Nov 25 '25	Sale	44.60	11,890	530,294	3,598,486	Nov 26 06:45 PM
ORBIMED ADVISORS LLC	Director	Nov 26 '25	Sale	44.49	1,600	71,184	3,596,886	Nov 26 06:45 PM
Thompson Peter A.	Director	Nov 24 '25	Sale	44.54	94,583	4,212,727	3,610,376	Nov 26 06:41 PM
Thompson Peter A.	Director	Nov 25 '25	Sale	44.60	11,890	530,294	3,598,486	Nov 26 06:41 PM
Thompson Peter A.	Director	Nov 26 '25	Sale	44.49	1,600	71,184	3,596,886	Nov 26 06:41 PM
OrbiMed Private Investments VI	Shareholder	Nov 24 '25	Proposed Sale	44.38	1,047,770	46,500,033		Nov 24 08:22 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Nov 21 '25	Sale	39.50	25,183	994,728	159,033	Nov 24 05:43 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Nov 20 '25	Sale	40.13	5,133	205,975	166,642	Nov 24 05:43 PM
RA Capital Healthcare Fund LP	Director	Nov 21 '25	Proposed Sale	43.66	1,210	52,829		Nov 21 04:24 PM
RA Capital Nexus Fund III, L.P	Director	Nov 21 '25	Proposed Sale	43.66	6,440	281,170		Nov 21 04:21 PM
RA Capital Nexus Fund, L.P.	Director	Nov 21 '25	Proposed Sale	43.66	9,924	433,282		Nov 21 04:19 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Nov 21 '25	Proposed Sale	43.66	7,609	332,209		Nov 21 04:17 PM
RA Capital Nexus Fund III, L.P	Director	Nov 20 '25	Proposed Sale	38.94	1,313	51,128		Nov 20 04:40 PM
RA Capital Nexus Fund, L.P.	Director	Nov 20 '25	Proposed Sale	38.94	2,023	78,776		Nov 20 04:35 PM
RA Capital Healthcare Fund LP	Director	Nov 20 '25	Proposed Sale	38.94	246	9,579		Nov 20 04:34 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Nov 20 '25	Proposed Sale	38.94	1,551	60,396		Nov 20 04:30 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Nov 17 '25	Sale	40.59	81,987	3,328,081	184,619	Nov 19 08:43 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Nov 19 '25	Sale	40.01	47,442	1,898,173	168,193	Nov 19 08:43 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Nov 18 '25	Sale	39.57	6,922	273,904	182,527	Nov 19 08:43 PM
RA Capital Healthcare Fund LP	Director	Nov 19 '25	Proposed Sale	39.12	2,278	89,115		Nov 19 05:21 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Nov 19 '25	Proposed Sale	38.41	14,334	550,568		Nov 19 05:16 PM
RA Capital Nexus Fund, L.P.	Director	Nov 19 '25	Proposed Sale	38.41	18,696	718,113		Nov 19 05:10 PM
RA Capital Nexus Fund III, L.P	Director	Nov 19 '25	Proposed Sale	38.41	12,134	466,066		Nov 19 05:04 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Nov 18 '25	Proposed Sale	39.04	2,092	81,671		Nov 18 05:22 PM
RA Capital Nexus Fund, L.P.	Director	Nov 18 '25	Proposed Sale	39.04	2,728	106,501		Nov 18 05:17 PM
RA Capital Nexus Fund III, L.P	Director	Nov 18 '25	Proposed Sale	39.04	1,770	69,100		Nov 18 05:09 PM
RA Capital Healthcare Fund LP	Director	Nov 18 '25	Proposed Sale	39.04	332	12,961		Nov 18 04:58 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Nov 17 '25	Proposed Sale	39.93	24,772	989,146		Nov 17 05:12 PM
RA Capital Nexus Fund, L.P.	Director	Nov 17 '25	Proposed Sale	39.93	32,310	1,290,138		Nov 17 05:04 PM
RA Capital Nexus Fund III, L.P	Director	Nov 17 '25	Proposed Sale	39.93	20,969	837,292		Nov 17 04:56 PM
RA Capital Healthcare Fund LP	Director	Nov 17 '25	Proposed Sale	39.93	3,936	157,164		Nov 17 04:46 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Oct 24 '25	Sale	39.50	311,000	12,284,500	219,867	Oct 28 09:05 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Oct 28 '25	Sale	39.58	62,610	2,478,104	209,391	Oct 28 09:05 PM
RA Capital Nexus Fund III, L.P	Director	Oct 28 '25	Proposed Sale	39.45	17,118	675,305		Oct 28 05:13 PM
RA Capital Healthcare Fund LP	Director	Oct 28 '25	Proposed Sale	39.45	3,624	142,967		Oct 28 05:07 PM
RA Capital Nexus Fund, L.P.	Director	Oct 28 '25	Proposed Sale	39.45	31,392	1,238,414		Oct 28 05:05 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Oct 28 '25	Proposed Sale	39.45	10,476	413,278		Oct 28 04:57 PM
RA Capital Nexus Fund, L.P.	Director	Oct 24 '25	Proposed Sale	39.21	122,271	4,794,246		Oct 24 06:05 PM
RA Capital Nexus Fund III, L.P	Director	Oct 24 '25	Proposed Sale	39.21	66,672	2,614,209		Oct 24 06:00 PM
RA Capital Healthcare Fund LP	Director	Oct 24 '25	Proposed Sale	39.21	14,116	553,488		Oct 24 05:53 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Oct 24 '25	Proposed Sale	39.21	107,941	4,232,367		Oct 24 05:39 PM
Cloonan Michael	President & CEO	Oct 21 '25	Option Exercise	6.11	99,800	609,778	580,875	Oct 22 05:39 PM
Cloonan Michael	President & CEO	Oct 21 '25	Sale	36.26	99,800	3,618,560	547,343	Oct 22 05:39 PM
Booth Bruce	Director	Oct 21 '25	Sale	34.22	88,878	3,041,683	686,567	Oct 21 05:12 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 21 '25	Proposed Sale	32.20	15,418	496,460		Oct 21 04:22 PM
Atlas Venture Fund XI, LP	Shareholder	Oct 21 '25	Proposed Sale	32.20	73,460	2,365,412		Oct 21 04:21 PM
MICHAEL CLOONAN	Director	Oct 21 '25	Proposed Sale	32.20	99,800	3,213,560		Oct 21 04:19 PM
Booth Bruce	Director	Oct 16 '25	Sale	32.35	169,260	5,476,168	722,301	Oct 20 09:39 PM
Booth Bruce	Director	Oct 17 '25	Sale	32.37	61,124	1,978,323	711,697	Oct 20 09:39 PM
Booth Bruce	Director	Oct 20 '25	Sale	32.09	55,985	1,796,611	701,985	Oct 20 09:39 PM
Atlas Venture Fund XI, LP	Shareholder	Oct 20 '25	Proposed Sale	31.93	46,273	1,477,497		Oct 20 04:46 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 20 '25	Proposed Sale	31.93	9,712	310,104		Oct 20 04:46 PM
Cloonan Michael	President & CEO	Oct 15 '25	Option Exercise	6.11	14,775	90,275	562,118	Oct 17 05:11 PM
Cloonan Michael	President & CEO	Oct 16 '25	Option Exercise	6.11	10,425	63,697	557,568	Oct 17 05:11 PM
Cloonan Michael	President & CEO	Oct 15 '25	Sale	31.11	14,775	459,662	547,343	Oct 17 05:11 PM
Cloonan Michael	President & CEO	Oct 16 '25	Sale	31.51	10,425	328,491	547,343	Oct 17 05:11 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 17 '25	Proposed Sale	32.71	10,604	346,857		Oct 17 04:27 PM
Atlas Venture Fund XI, LP	Shareholder	Oct 17 '25	Proposed Sale	32.72	50,520	1,653,014		Oct 17 04:27 PM
Atlas Venture Fund XI, LP	Shareholder	Oct 16 '25	Proposed Sale	30.91	139,897	4,324,216		Oct 16 05:01 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 16 '25	Proposed Sale	30.91	29,363	907,610		Oct 16 05:00 PM
MICHAEL CLOONAN	Director	Oct 16 '25	Proposed Sale	30.91	200	6,182		Oct 16 04:34 PM
Booth Bruce	Director	Oct 15 '25	Sale	30.61	115,856	3,545,798	751,664	Oct 15 06:33 PM
Booth Bruce	Director	Oct 13 '25	Sale	30.38	58,232	1,769,101	771,867	Oct 15 06:33 PM
Booth Bruce	Director	Oct 10 '25	Sale	29.98	20,238	606,735	781,969	Oct 15 06:33 PM
Booth Bruce	Director	Oct 14 '25	Sale	29.95	606	18,150	771,762	Oct 15 06:33 PM
MICHAEL CLOONAN	Director	Oct 15 '25	Proposed Sale	29.94	25,000	748,500		Oct 15 04:38 PM
Atlas Venture Fund XI, LP	Shareholder	Oct 13 '25	Proposed Sale	29.42	48,130	1,415,985		Oct 14 04:23 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 13 '25	Proposed Sale	29.42	10,102	297,201		Oct 14 04:22 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 10 '25	Proposed Sale	28.35	3,511	99,537		Oct 10 04:24 PM
Atlas Venture Fund XI, LP	Shareholder	Oct 10 '25	Proposed Sale	28.35	16,727	474,210		Oct 10 04:24 PM
Booth Bruce	Director	Oct 03 '25	Sale	30.00	37,746	1,132,380	787,527	Oct 07 05:00 PM
Booth Bruce	Director	Oct 06 '25	Sale	29.95	11,800	353,410	785,480	Oct 07 05:00 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 06 '25	Proposed Sale	30.01	2,047	61,430		Oct 06 04:51 PM
Atlas Venture Fund XI, LP	Shareholder	Oct 06 '25	Proposed Sale	30.01	9,753	292,688		Oct 06 04:51 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 03 '25	Proposed Sale	29.30	6,548	191,856		Oct 03 04:44 PM
Atlas Venture Fund XI, LP	Shareholder	Oct 03 '25	Proposed Sale	29.30	31,198	914,101		Oct 03 04:44 PM
Booth Bruce	Director	Sep 29 '25	Sale	30.09	66,105	1,989,099	796,259	Oct 01 06:04 PM
Booth Bruce	Director	Sep 30 '25	Sale	30.06	12,388	372,383	794,110	Oct 01 06:04 PM
Booth Bruce	Director	Oct 01 '25	Sale	29.95	200	5,990	794,075	Oct 01 06:04 PM
Atlas Venture Fund XI, LP	Shareholder	Oct 01 '25	Proposed Sale	29.41	165	4,853		Oct 01 04:17 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 01 '25	Proposed Sale	29.41	35	1,029		Oct 01 04:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SION

Sionna Therapeutics Inc

Upgrade your FINVIZ experience